<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "2: performance events", fill: "#efbbcc"},
{source: "2: performance events", target: "2: developments", fill: "#efbbcc"},
{source: "2: developments", target: "2: future revenue", fill: "#efbbcc"},
{source: "2: future revenue", target: "2: profits expenses income", fill: "#efbbcc"},
{source: "2: profits expenses income", target: "2: earnings per", fill: "#efbbcc"},
{source: "2: earnings per", target: "2: general optimism about future", fill: "#efbbcc"},
{source: "2: performance events", target: "16: proprietary", fill: "#4b0082"},
{source: "16: proprietary", target: "16: eClinical software", fill: "#4b0082"},
{source: "16: eClinical software", target: "16: clinical trials continued enhancement", fill: "#4b0082"},
{source: "16: clinical trials continued enhancement", target: "16: necessary", fill: "#4b0082"},
{source: "16: necessary", target: "16: additional", fill: "#4b0082"},
{source: "16: additional", target: "16: everchanging", fill: "#4b0082"},
{source: "16: everchanging", target: "16: expectations", fill: "#4b0082"},
{source: "16: proprietary", target: "20: significant fluctuations", fill: "#f0e130"},
{source: "20: significant fluctuations", target: "20: new contracts", fill: "#f0e130"},
{source: "20: new contracts", target: "20: clinical trials", fill: "#f0e130"},
{source: "20: clinical trials", target: "20: participate", fill: "#f0e130"},
{source: "20: participate", target: "20: clinical trial sponsor decisions", fill: "#f0e130"},
{source: "20: clinical trial sponsor decisions", target: "20: conduct new clinical", fill: "#f0e130"},
{source: "20: conduct new clinical", target: "20: delay ongoing trials", fill: "#f0e130"},
{source: "20: significant fluctuations", target: "21: expense levels", fill: "#fd0e35"},
{source: "21: expense levels", target: "21: expectations as", fill: "#fd0e35"},
{source: "21: expectations as", target: "21: certain extent", fill: "#fd0e35"},
{source: "21: expense levels", target: "23: relatively", fill: "#c0362c"},
{source: "23: relatively", target: "23: significant", fill: "#c0362c"},
{source: "23: significant", target: "23: operations", fill: "#c0362c"},
{source: "23: relatively", target: "25: early stage", fill: "#003153"},
{source: "25: early stage", target: "25: development", fill: "#003153"},
{source: "25: early stage", target: "26: standardized", fill: "#4f666a"},
{source: "26: standardized", target: "26: collection", fill: "#4f666a"},
{source: "26: collection", target: "26: management", fill: "#4f666a"},
{source: "26: management", target: "26: clinical research data represent", fill: "#4f666a"},
{source: "26: clinical research data represent", target: "26: significant departure from", fill: "#4f666a"},
{source: "26: significant departure from", target: "26: traditional clinical research practices", fill: "#4f666a"},
{source: "26: traditional clinical research practices", target: "26: clinical trial sponsors", fill: "#4f666a"},
{source: "26: standardized", target: "34: lose revenues", fill: "#4d5d53"},
{source: "34: lose revenues", target: "34: clinical trial sponsor decides", fill: "#4d5d53"},
{source: "34: clinical trial sponsor decides", target: "34: participate", fill: "#4d5d53"},
{source: "34: lose revenues", target: "35: may lose future revenue", fill: "#ffcba4"},
{source: "35: may lose future revenue", target: "35: major customers", fill: "#ffcba4"},
{source: "35: major customers", target: "35: development expenditures", fill: "#ffcba4"},
{source: "35: may lose future revenue", target: "36: primary customers", fill: "#d8bfd8"},
{source: "36: primary customers", target: "36: pharmaceutical industry", fill: "#d8bfd8"},
{source: "36: primary customers", target: "41: operations could", fill: "#5218fa"},
{source: "41: operations could", target: "41: materially", fill: "#5218fa"},
{source: "41: materially", target: "41: adversely affected by", fill: "#5218fa"},
{source: "41: adversely affected by", target: "41: economic downturn", fill: "#5218fa"},
{source: "41: economic downturn", target: "41: consolidations", fill: "#5218fa"},
{source: "41: consolidations", target: "41: pharmaceutical", fill: "#5218fa"},
{source: "41: pharmaceutical", target: "41: biotechnology industries", fill: "#5218fa"},
{source: "41: biotechnology industries", target: "41: industries", fill: "#5218fa"},
{source: "41: industries", target: "41: industries research", fill: "#5218fa"},
{source: "41: industries research", target: "41: development", fill: "#5218fa"},
{source: "41: development", target: "41: expenditures", fill: "#5218fa"},
{source: "41: expenditures", target: "41: regulatory environment", fill: "#5218fa"},
{source: "41: regulatory environment", target: "41: which companies", fill: "#5218fa"},
{source: "41: operations could", target: "63: competitive position", fill: "#b2ec5d"},
{source: "63: competitive position", target: "63: adversely affected", fill: "#b2ec5d"},
{source: "63: adversely affected", target: "63: intellectual property rights", fill: "#b2ec5d"},
{source: "63: intellectual property rights", target: "63: infringe upon", fill: "#b2ec5d"},
{source: "63: competitive position", target: "71: acquisition", fill: "#eee8aa"},
{source: "71: acquisition", target: "71: ClickFind ", fill: "#eee8aa"},
{source: "71: acquisition", target: "72: new product suite", fill: "#f8de7e"},
{source: "72: new product suite", target: "72: eClinical will play", fill: "#f8de7e"},
{source: "72: eClinical will play", target: "72: significant role", fill: "#f8de7e"},
{source: "72: significant role", target: "72: ASP for the EDC ", fill: "#f8de7e"},
{source: "72: new product suite", target: "74: Acquisitions ", fill: "#2a52be"},
{source: "74: Acquisitions ", target: "74: also may involve", fill: "#2a52be"},
{source: "74: also may involve", target: "74: special risks", fill: "#2a52be"},
{source: "74: special risks", target: "74: adverse shortterm effects on", fill: "#2a52be"},
{source: "74: adverse shortterm effects on", target: "74: potentially dilutive issuances", fill: "#2a52be"},
{source: "74: potentially dilutive issuances", target: "74: equity securities", fill: "#2a52be"},
{source: "74: equity securities", target: "74: contingent liabilities diversion", fill: "#2a52be"},
{source: "74: contingent liabilities diversion", target: "74: managements attention dependence", fill: "#2a52be"},
{source: "74: managements attention dependence", target: "74: on retention hiring", fill: "#2a52be"},
{source: "74: on retention hiring", target: "74: key personnel", fill: "#2a52be"},
{source: "74: key personnel", target: "74: risks associated with", fill: "#2a52be"},
{source: "74: risks associated with", target: "74: unanticipated problems", fill: "#2a52be"},
{source: "74: unanticipated problems", target: "74: legal liabilities", fill: "#2a52be"},
{source: "74: legal liabilities", target: "74: which could", fill: "#2a52be"},
{source: "74: which could", target: "74: operations", fill: "#2a52be"},
{source: "74: operations", target: "74: financial condition", fill: "#2a52be"},
{source: "74: Acquisitions ", target: "81: Furthermore ", fill: "#414833"},
{source: "81: Furthermore ", target: "81: will incur additional costs", fill: "#414833"},
{source: "81: will incur additional costs", target: "81: two parallel production", fill: "#414833"},
{source: "81: Furthermore ", target: "85: common shares could", fill: "#73c2fb"},
{source: "85: common shares could", target: "85: adversely affected by", fill: "#73c2fb"},
{source: "85: adversely affected by", target: "85: common shares issued", fill: "#73c2fb"},
{source: "85: common shares issued", target: "85: acquisition", fill: "#73c2fb"},
{source: "85: common shares could", target: "87: outstanding common shares as", fill: "#534b4f"},
{source: "87: outstanding common shares as", target: "87: February ", fill: "#534b4f"},
{source: "87: outstanding common shares as", target: "89: common shares", fill: "#4169e1"},
{source: "89: common shares", target: "89: shareholders", fill: "#4169e1"},
{source: "89: shareholders", target: "89: common shares thus", fill: "#4169e1"},
{source: "89: common shares thus", target: "89: further decline", fill: "#4169e1"},
{source: "89: common shares", target: "START_HERE", fill: "#4169e1"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Ease</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Offer peace proposal</td>
    </tr>
    <tr>
      <td>Consult</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Psychological state</td>
    </tr>
    <tr>
      <td>Yield position</td>
    </tr>
    <tr>
      <td>Reward</td>
    </tr>
    <tr>
      <td>Grant</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arrested_Development">Arrested Development</a></td>
      <td>Arrested Development is an American television sitcom created by Mitchell Hurwitz, which originally aired on Fox for three seasons from  2003 to 2006, followed by a two-season revival on Netflix from 2013 to 2019. The show follows the Bluths, a formerly wealthy dysfunctional family.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sustainable_development">Sustainable development</a></td>
      <td>Sustainable development is an organizing principle for meeting human development goals while also sustaining the ability of natural systems to provide the natural resources and ecosystem services on which the economy and society depend. The desired result is a state of society where living conditions and resources are used to continue to meet human needs without undermining the integrity and stability of the natural system.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Proprietary_software">Proprietary software</a></td>
      <td>Proprietary software, also known as non-free software or closed-source software, is computer software for which the software's publisher or another person reserves some licensing rights to use, modify, share modifications, or share the software, restricting user freedom with the software they lease. It is the opposite of open-source or free software.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Necessary_Roughness_(album)">Necessary Roughness (album)</a></td>
      <td>Necessary Roughness is the debut and so far only official studio album from the American hip-hop artist, The Lady of Rage. The album was released on June 24, 1997.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/ClinicalTrials.gov">ClinicalTrials.gov</a></td>
      <td>ClinicalTrials.gov is a registry of clinical trials. It is run by the United States National Library of Medicine (NLM) at the National Institutes of Health, and is the largest clinical trials database, holding registrations from over 329,000 trials from 209 countries.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Clinical_trials_in_India">Clinical trials in India</a></td>
      <td>Clinical trials in India refers to clinical research in India in which researchers test drugs and other treatments on research participants. NDCTR 2019 and section 3.7.1 to 3.7.3 of ICMR guidelines requires that all researchers conducting a clinical trial must publicly document it in the Clinical Trials Registry - India.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Clinical_trials_on_Ayurveda">Clinical trials on Ayurveda</a></td>
      <td>Clinical trials on Ayurveda refers to any clinical trials done on Ayurvedic treatment. Ayurveda is a traditional medicine system in India and like other cultural medical practices includes both conventional medicine and also complementary and alternative medicine.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Clinical_research">Clinical research</a></td>
      <td>Clinical research is a branch of healthcare science that determines the safety and effectiveness (efficacy) of medications, devices, diagnostic products and treatment regimens intended for human use. These may be used for prevention, treatment, diagnosis or for relieving symptoms of a disease.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Expense">Expense</a></td>
      <td>An expense is an item requiring an outflow of money, or any form of fortune in general, to another person or group as payment for an item, service, or other category of costs. For a tenant, rent is an expense.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Internet">Internet</a></td>
      <td>In finance and economics, interest is payment from a borrower or deposit-taking financial institution to a lender or depositor of an amount above repayment of the principal sum (that is, the amount borrowed), at a particular rate. It is distinct from a fee which the borrower may pay the lender or some third party.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arithmetic">Arithmetic</a></td>
      <td>Arithmetic (from Ancient Greek  ἀριθμός (arithmós) 'number', and  τική [τέχνη] (tikḗ [tékhnē]) 'art, craft') is an elementary part of mathematics that consists of the study of the properties of the traditional operations on numbers—addition, subtraction, multiplication, division, exponentiation, and extraction of roots. In the 19th century, Italian mathematician Giuseppe Peano formalized arithmetic with his Peano axioms, which are highly important to the field of mathematical logic today.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Special_Activities_Center">Special Activities Center</a></td>
      <td>The Special Activities Center (SAC) is a division of the Central Intelligence Agency responsible for covert operations and paramilitary operations. The unit was named Special Activities Division (SAD) prior to 2015.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_research">Operations research</a></td>
      <td>Operations research (British English: operational research), often shortened to the initialism OR, is a discipline that deals with the development and application of advanced analytical methods to improve decision-making. It is sometimes considered to be a subfield of mathematical sciences.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bitwise_operation">Bitwise operation</a></td>
      <td>In computer programming, a bitwise operation operates on a bit string, a bit array or a binary numeral (considered as a bit string) at the level of its individual bits. It is a fast and simple action, basic to the higher-level arithmetic operations and directly supported by the processor.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Management">Management</a></td>
      <td>Management (or managing) is the administration of an organization, whether it is a business, a non-profit organization, or a government body. It is the art and science of managing resources of the business.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Medical_guideline">Medical guideline</a></td>
      <td>A medical guideline (also called a clinical guideline, standard treatment guideline, or clinical practice line) is a document with the aim of guiding decisions and criteria regarding diagnosis, management, and treatment in specific areas of healthcare. Such documents have been in use for thousands of years during the entire history of medicine.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Market_power">Market power</a></td>
      <td>In economics, market power refers to the ability of a firm to influence the price at which it sells a product or service by manipulating either the supply or demand of the product or service to increase economic profit. In other words, market power occurs if a firm does not face a perfectly elastic demand curve and can set its price (P) above marginal cost (MC) without losing revenue.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_countries_by_total_health_expenditure_per_capita">List of countries by total health expenditure per capita</a></td>
      <td>This article includes 2 lists of countries of the world and their total expenditure on health per capita. Total expenditure includes both public and private expenditures.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Public_expenditure">Public expenditure</a></td>
      <td>Public expenditure is spending made by the government of a country on collective needs and wants, such as pension, provisions (which includes education, healthcare and housing), security, infrastructure, etc. Until the 19th century, public expenditure was limited as laissez faire philosophies believed that money left in private hands could bring better returns.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pharmaceutical_manufacturing">Pharmaceutical manufacturing</a></td>
      <td>Pharmaceutical manufacturing is the process of industrial-scale synthesis of pharmaceutical drugs as part of the pharmaceutical industry.  The process of drug manufacturing can be broken down into a series of unit operations, such as milling, granulation, coating, tablet pressing, and others.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Ivor_Montagu">Ivor Montagu</a></td>
      <td>Ivor Goldsmid Samuel Montagu (23 April 1904, in Kensington, London – 5 November 1984, in Watford) was an English filmmaker, screenwriter, producer, film critic, writer, table tennis player, and Communist activist in the 1930s. He helped to develop a lively intellectual film culture in Britain during the interwar years, and was also the founder of the International Table Tennis Federation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Intellectual_property">Intellectual property</a></td>
      <td>Intellectual property (IP) is a category of property that includes intangible creations of the human intellect. There are many types of intellectual property, and some countries recognize more than others.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Intellectual_property_infringement">Intellectual property infringement</a></td>
      <td>An intellectual property (IP) infringement is the infringement or violation of an intellectual property right. There are several types of intellectual property rights, such as copyrights, patents, trademarks, industrial designs, and trade secrets.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Language_acquisition">Language acquisition</a></td>
      <td>Language acquisition is the process by which humans acquire the capacity to perceive and comprehend language (in other words, gain the ability to be aware of language and to understand it), as well as to produce and use words and sentences to communicate.\nLanguage acquisition involves structures, rules and representation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Data_acquisition">Data acquisition</a></td>
      <td>Data acquisition is the process of sampling signals that measure real world physical conditions and converting the resulting samples into digital numeric values that can be manipulated by a computer. Data acquisition systems, abbreviated by the initialisms DAS, DAQ, or DAU, typically convert analog waveforms into digital values for processing.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Resource_acquisition_is_initialization">Resource acquisition is initialization</a></td>
      <td>Resource acquisition is initialization (RAII) is a programming idiom used in several object-oriented, statically-typed programming languages to describe a particular language behavior.  In RAII, holding a resource is a class invariant, and is tied to object lifetime.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Rules_of_Acquisition">Rules of Acquisition</a></td>
      <td>In the fictional Star Trek universe, the Rules of Acquisition are a collection of sacred business proverbs of the ultra-capitalist race known as the Ferengi.\nThe first mention of rules in the Star Trek universe was in "The Nagus", an episode of the TV series Star Trek: Deep Space Nine (Season 1, Episode 10).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Right_to_Fair_Compensation_and_Transparency_in_Land_Acquisition,_Rehabilitation_and_Resettlement_Act,_2013">Right to Fair Compensation and Transparency in Land Acquisition, Rehabilitation and Resettlement Act, 2013</a></td>
      <td>The Right to Fair Compensation and Transparency in Land Acquisition, Rehabilitation and Resettlement Act, 2013 (also Land Acquisition Act, 2013 or LARR Act or RFCTLARR Act) is an Act of Indian Parliament that regulates land acquisition and lays down the procedure and rules for granting compensation, rehabilitation and resettlement to the affected persons in India. The Act has provisions to provide fair compensation to those whose land is taken away, brings transparency to the process of acquisition of land to set up factories or buildings, infrastructural projects and assures rehabilitation of those affected.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Adobe_Creative_Suite">Adobe Creative Suite</a></td>
      <td>Adobe Creative Suite (CS) is a discontinued software suite of graphic design, video editing, and web development applications developed by Adobe Systems. Each edition consisted of several Adobe applications, such .</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Equity_(finance)">Equity (finance)</a></td>
      <td>In finance, equity is ownership of assets that may have debts or other liabilities attached to them. Equity is measured for accounting purposes by subtracting liabilities from the value of the assets.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Non-price_competition">Non-price competition</a></td>
      <td>Non-price competition is a marketing strategy "in which one firm tries to distinguish its product or service from competing products on the basis of attributes like design and workmanship". It often occurs in imperfectly competitive markets because it exists between two or more producers that sell goods and services at the same prices but compete to increase their respective market shares through non-price measures such as marketing schemes and greater quality.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Penny_stock">Penny stock</a></td>
      <td>Penny stocks are common shares of small public companies that trade for less than one dollar per share.The U.S. Securities and Exchange Commission (SEC) uses the term "Penny stock" to refer to a security, a financial instrument which represents a given financial value, issued by small public companies that trade at less than $5 per share. Penny stocks are priced over-the-counter, rather than on the trading floor.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Common_stock">Common stock</a></td>
      <td>Common stock is a form of corporate equity ownership, a type of security. The terms voting share and ordinary share are also used frequently outside of the United States.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Hindalco_Industries">Hindalco Industries</a></td>
      <td>Hindalco Industries Limited an Indian aluminium and copper manufacturing company, is a subsidiary of the Aditya Birla Group. Its headquarters are at Mumbai, Maharashtra, India.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Shareholder">Shareholder</a></td>
      <td>A shareholder (in the United States often referred to as stockholder) of a corporation is an individual or legal entity (such as another corporation, a body politic, a trust or partnership) that is registered by the corporation as the legal owner of shares of the share capital of a public or private corporation. Shareholders may be referred to as members of a corporation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Berkshire_Hathaway">Berkshire Hathaway</a></td>
      <td>Berkshire Hathaway Inc. () is an American multinational conglomerate holding company headquartered in Omaha, Nebraska, United States.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Stockholder_of_record">Stockholder of record</a></td>
      <td>Stockholder of record is the name of an individual or entity shareholder that an issuer carries in its shareholder register as the registered holder (not necessarily the beneficial owner) of the issuer's securities. Dividends and other distributions are paid only to shareholders of record.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>DATATRAK INTERNATIONAL INC      Item 1A Risk Factors                                                                               7     ITEM 1A   RISK FACTORS          Certain statements made in this <font color="blue">Annual Report </font>on Form 10-K contain     forward-looking  statements  within  the meaning of Section 21E of the     Securities  <font color="blue">Exchange Act</font> of 1934 (“<font color="blue">Exchange Act</font>”)</td>
    </tr>
    <tr>
      <td>All statements that     address operating performance, events or <font color="blue"><font color="blue">development</font>s</font> that we anticipate     will occur in the future, including statements related to <font color="blue">future revenue</font>,     profits, expenses, income and <font color="blue">earnings per</font> share or statements expressing     <font color="blue">general optimism about future</font> results, are forward-looking statements</td>
    </tr>
    <tr>
      <td>In     addition,  words such as “expects,” “anticipates,” “intends,” “plans,”     “believes,” “estimates,” <font color="blue">variations</font> of such words, and similar <font color="blue">expressions</font>     are  intended  to identify forward-looking statements</td>
    </tr>
    <tr>
      <td>Forward-looking     statements are subject to the <font color="blue">safe harbors</font> created in the <font color="blue">Exchange Act</font></td>
    </tr>
    <tr>
      <td>Forward-looking statements are subject to <font color="blue">numerous assumptions</font> and     risks and <font color="blue">uncertainties</font> that may cause our actual results or performance to     be <font color="blue"><font color="blue">materially</font> different from</font> any future results or performance expressed or     implied by the forward-looking statements</td>
    </tr>
    <tr>
      <td>We have identified the following     important factors, <font color="blue">which could</font> cause our <font color="blue">actual operational</font> or financial     results to <font color="blue">differ <font color="blue">materially</font> from</font> any <font color="blue">projections</font>, estimates, forecasts or     other  forward-looking  statements  made by or on our behalf</td>
    </tr>
    <tr>
      <td>Under no     <font color="blue">circumstances</font> should the factors listed below be construed as an <font color="blue">exhaustive</font>     list of all factors that could cause actual results to differ <font color="blue">materially</font>     from  those  expressed  in forward-looking statements</td>
    </tr>
    <tr>
      <td>We undertake no     <font color="blue">obligation</font> to review or confirm analysts’ <font color="blue">expectations</font> or estimates or to     <font color="blue">release publicly</font> any revisions to                                         7       _________________________________________________________________           forward-looking statements contained herein to take <font color="blue">into account events</font> or     <font color="blue">circumstances</font> that occur after the date of this <font color="blue">Annual Report </font>on Form 10-K     In addition, we do not undertake any <font color="blue">responsibility</font> to <font color="blue">update publicly</font> the     occurrence of unanticipated events, which may cause actual results to differ     from those expressed or implied by the forward-looking statements contained     herein</td>
    </tr>
    <tr>
      <td>We have a limited operating history and we have not <font color="blue">until recently</font> had     <font color="blue">profitable <font color="blue">operations</font></font></td>
    </tr>
    <tr>
      <td>We began providing EDC services in 1997 and have a limited operating     history  upon which our <font color="blue">performance may</font> be evaluated</td>
    </tr>
    <tr>
      <td>Although we were     profitable in 2004 and 2005, we had <font color="blue">previously</font> recognized operating losses     in each year since 1997</td>
    </tr>
    <tr>
      <td>Our cumulative operating loss since 1997 from EDC     <font color="blue">operations</font> totaled dlra37cmam411cmam000 at <font color="blue">December </font>31, 2005</td>
    </tr>
    <tr>
      <td>However, any number of factors, including, but     not limited to, <font color="blue">termination</font> or delays in contracts, <font color="blue">inability</font> to grow and     convert backlog into revenue or being unable to quickly reduce costs if     required, could cause us to record losses in 2006 and in <font color="blue">future periods</font></td>
    </tr>
    <tr>
      <td>Although our <font color="blue">proprietary</font> DATATRAK EDC® and DATATRAK eClinical™ software     solutions  have been used in <font color="blue"><font color="blue">clinical trial</font>s</font>, continued enhancement is     <font color="blue">necessary</font>  to  provide  <font color="blue">additional</font>  functions and services to meet the     ever-changing needs and <font color="blue">expectations</font> of our customers</td>
    </tr>
    <tr>
      <td>To date we have had     limited  EDC <font color="blue">revenue from which</font> to support the costs of this continued     <font color="blue">software enhancement</font></td>
    </tr>
    <tr>
      <td>Our potential <font color="blue">future revenue</font> may not be sufficient to     <font color="blue">absorb corporate overhead</font> and other fixed operating costs that will be     <font color="blue">necessary</font> for our <font color="blue">future success</font></td>
    </tr>
    <tr>
      <td>Our quarterly results <font color="blue">fluctuate <font color="blue">significant</font>ly</font></td>
    </tr>
    <tr>
      <td>We are subject to <font color="blue"><font color="blue">significant</font> fluctuations</font> in quarterly results caused     by many factors, including       •   our success in obtaining <font color="blue">new contracts</font>,         •   the size and duration of the <font color="blue"><font color="blue">clinical trial</font>s</font> in which we <font color="blue">participate</font>,     and         •   the timing of <font color="blue"><font color="blue">clinical trial</font> <font color="blue">sponsor decisions</font></font> to <font color="blue">conduct new clinical</font>     trials or cancel or <font color="blue">delay ongoing trials</font></td>
    </tr>
    <tr>
      <td>Our  <font color="blue">expense levels</font> are based in part on our <font color="blue">expectations</font> as to future     revenue and to a <font color="blue">certain extent</font> are fixed</td>
    </tr>
    <tr>
      <td>We cannot make <font color="blue">assurances as</font> to     our revenues in any <font color="blue">given period</font>, and we may be unable to <font color="blue">adjust expenses</font> in     a <font color="blue">timely manner</font> to compensate for any <font color="blue">unexpected revenue shortfall</font></td>
    </tr>
    <tr>
      <td>As a     result of our <font color="blue">relatively</font> small <font color="blue">revenue base</font>, any <font color="blue">significant</font> shortfall in     revenue  recognized during a particular period could have an immediate     adverse  effect on our income from <font color="blue">operations</font> and <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td><font color="blue">Volatility </font>in our quarterly results may <font color="blue">adversely</font> affect the <font color="blue">market price</font> of     our <font color="blue">common shares</font></td>
    </tr>
    <tr>
      <td>Our  business  strategies are unproven and we are in an <font color="blue">early stage</font> of     <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>Our efforts to establish a <font color="blue">standardized</font> EDC process for <font color="blue">collection</font> and     <font color="blue">management</font> of <font color="blue">clinical research data represent</font> a <font color="blue">significant</font> departure from     the <font color="blue">traditional clinical research practices</font> of <font color="blue"><font color="blue">clinical trial</font> sponsors</font></td>
    </tr>
    <tr>
      <td>The     long-term viability of our business <font color="blue">remains unproven</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">strategy may</font> not     <font color="blue">gain <font color="blue">acceptance</font> among sponsors</font> of clinical research, research sites or     <font color="blue">investigators</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">prospects must</font> be considered in light of the risks,     expenses and <font color="blue"><font color="blue">difficult</font>ies frequently encountered by companies</font> in their early     stages of <font color="blue">development</font>, particularly companies in new and <font color="blue">rapidly evolving</font>     markets</td>
    </tr>
    <tr>
      <td>We <font color="blue">may lose revenue</font> if we experience delays in <font color="blue"><font color="blue">clinical trial</font>s</font> or if we lose     contracts</td>
    </tr>
    <tr>
      <td>Although our contracts provide that we are entitled to receive revenue     <font color="blue">earned through</font> the date of <font color="blue">termination</font>, our <font color="blue">customers generally</font> are free to     delay or terminate a <font color="blue">clinical trial</font> or our contract related to                                         8       _________________________________________________________________           the trial at any time</td>
    </tr>
    <tr>
      <td>The length of a typical <font color="blue">clinical trial</font> contract     <font color="blue">varies from several months</font> to <font color="blue">several years</font></td>
    </tr>
    <tr>
      <td>Clinical <font color="blue">trial sponsors may</font>     delay or terminate <font color="blue"><font color="blue">clinical trial</font>s</font> for <font color="blue">several reasons</font>, including       •   unexpected results or <font color="blue">adverse patient reactions</font> to a potential     product,         •   inadequate <font color="blue">patient enrollment</font> or <font color="blue">investigator recruitment</font>,         •   <font color="blue">manufacturing problems</font> resulting in shortages of a <font color="blue">potential product</font>,     or         •   <font color="blue">sponsor decisions</font> to de-emphasize or terminate a <font color="blue">particular trial</font> or     drug</td>
    </tr>
    <tr>
      <td>We  may  <font color="blue">lose revenues</font> if a <font color="blue">clinical trial</font> sponsor decides to delay or     terminate a trial in which we <font color="blue">participate</font></td>
    </tr>
    <tr>
      <td>We may lose <font color="blue">future revenue</font> if our <font color="blue">major customers</font> decrease their research     and <font color="blue">development</font> <font color="blue">expenditures</font>, or if we lose any of our <font color="blue">major customers</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">primary customers</font> are companies in the <font color="blue"><font color="blue">pharmaceutical</font> industry</font></td>
    </tr>
    <tr>
      <td>Our     business  is  <font color="blue">substantially</font>  <font color="blue">dependent on</font> the research and <font color="blue">development</font>     <font color="blue">expenditures</font> of companies in this industry</td>
    </tr>
    <tr>
      <td>The extent to which we rely on     <font color="blue">revenue from one customer varies from period</font> to period, depending upon,     among other things, our ability to <font color="blue">generate new</font> business and the timing and     size of <font color="blue"><font color="blue">clinical trial</font>s</font></td>
    </tr>
    <tr>
      <td>In light of our small <font color="blue">revenue base</font>, we are more     <font color="blue">dependent on</font> <font color="blue">major customers</font> than many of the <font color="blue">larger participants</font> in the EDC     industry</td>
    </tr>
    <tr>
      <td>During 2005, one customer accounted for 59prca of our <font color="blue">total revenue</font>     for the year</td>
    </tr>
    <tr>
      <td>Our <font color="blue">operations</font> could be <font color="blue">materially</font> and <font color="blue">adversely</font> affected by,     among other things,       •   any <font color="blue">economic downturn</font> or <font color="blue">consolidations</font> in the <font color="blue">pharmaceutical</font> or     <font color="blue">bio<font color="blue">technology</font> <font color="blue">industries</font></font>,          •     any  decrease  in  these <font color="blue">industries</font>’ research and <font color="blue">development</font>     <font color="blue">expenditures</font>, or         •   changes in the <font color="blue"><font color="blue">regulatory</font> environment</font> in <font color="blue">which companies</font> in these     <font color="blue">industries</font> operate</td>
    </tr>
    <tr>
      <td>Changes in <font color="blue">government</font> <font color="blue">regulations</font> relating to the <font color="blue">health care industry could</font>     have a material adverse effect on the demand for our services</td>
    </tr>
    <tr>
      <td>Demand  for  our services is largely a function of the <font color="blue">regulatory</font>     <font color="blue">requirements</font> associated with the approval of a New Drug Application by the     FDA These <font color="blue">requirements</font> are more stringent and thus more <font color="blue">burdensome than</font>     those <font color="blue">imposed by</font> many other developed countries</td>
    </tr>
    <tr>
      <td>In recent years, efforts     have been made to streamline the <font color="blue">drug approval process</font> and coordinate US     <font color="blue">standards with</font> those of other developed countries</td>
    </tr>
    <tr>
      <td>Changes in the level of     regulation,  including  a <font color="blue">relaxation</font> in <font color="blue">regulatory</font> <font color="blue">requirements</font> or the     <font color="blue">introduction</font> of <font color="blue">simplified drug approval procedures could reduce</font> the demand     for our services</td>
    </tr>
    <tr>
      <td>Several <font color="blue">competing proposals</font> to reform the system of health     <font color="blue">care delivery</font> in the <font color="blue">United States </font>have been considered by <font color="blue">Congress </font>from     time to time</td>
    </tr>
    <tr>
      <td>To date, none of these proposals have <font color="blue">been adopted</font></td>
    </tr>
    <tr>
      <td>The FDA’s <font color="blue">guidelines</font> and rules related to the use of <font color="blue">computerized</font>     systems in <font color="blue"><font color="blue">clinical trial</font>s</font> are still in the <font color="blue">early stage</font>s of <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>Our     <font color="blue">software may</font> not continue to <font color="blue">comply with</font> these <font color="blue">guidelines</font> and rules as they     develop, and <font color="blue">corresponding</font> changes to our <font color="blue">product may</font> be required</td>
    </tr>
    <tr>
      <td>Any     release of FDA guidance that is <font color="blue">significant</font>ly inconsistent with the design     of DATATRAK EDC® or DATATRAK eClinical™ may cause us to incur substantial     costs to remain in <font color="blue">compliance with</font> FDA guidance and <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>The EDC market, which is still developing, and <font color="blue">must compete with</font> the     traditional  <font color="blue">paper method</font> of collecting <font color="blue">clinical trial</font> data, is highly     fragmented</td>
    </tr>
    <tr>
      <td>The <font color="blue">major competitors</font> in the EDC market include       •   EDC <font color="blue">software vendors</font>,         •   <font color="blue">clinical trial</font> data service companies that use paper for data     <font color="blue">collection</font>,         •   <font color="blue">vendors offering single</font> component solutions and         •   in-house <font color="blue">development</font> efforts within large <font color="blue">pharmaceutical</font> companies</td>
    </tr>
    <tr>
      <td>Our current and <font color="blue">potential future competitors</font> have or may have <font color="blue">substantially</font>     greater resources, greater name recognition and more extensive customer     bases that could be leveraged, thereby gaining market share or product     <font color="blue">acceptance</font> to our detriment</td>
    </tr>
    <tr>
      <td>We may not be able to capture or establish the     market presence <font color="blue">necessary</font> to <font color="blue">effectively compete</font> in this emerging sector of     the <font color="blue">clinical research industry</font></td>
    </tr>
    <tr>
      <td>We may be subject to <font color="blue">liability</font> for <font color="blue">potential breaches</font> of contracts or losses     relating to the <font color="blue">unauthorized release</font> of <font color="blue">clinical trial</font> data</td>
    </tr>
    <tr>
      <td>Our services are supported by telecommunications equipment, software,     operating protocols and <font color="blue">proprietary</font> applications for high-speed transmission     of large quantities of <font color="blue">data among multiple locations</font></td>
    </tr>
    <tr>
      <td>In addition, clinical     <font color="blue">pharmaceutical</font> and medical device research requires the review and handling     of large amounts of <font color="blue">patient data</font></td>
    </tr>
    <tr>
      <td><font color="blue">Potential </font><font color="blue">liability</font> may arise from a     breach of contract or a loss of or <font color="blue">unauthorized release</font> of <font color="blue">clinical trial</font>     data</td>
    </tr>
    <tr>
      <td>If  we  were  forced to undertake the defense of, or were found     <font color="blue">financially responsible</font> for, claims <font color="blue">based upon</font> these types of losses, our     <font color="blue">financial resources could</font> be diminished</td>
    </tr>
    <tr>
      <td>We maintain a dlra5cmam000cmam000 errors and     omissions professional <font color="blue">liability</font> insurance policy to cover claims that may     be <font color="blue">brought against us</font></td>
    </tr>
    <tr>
      <td>This <font color="blue">coverage may</font> not be adequate, and insurance may     not continue to be available to us, in the future</td>
    </tr>
    <tr>
      <td>Our <font color="blue">competitive position</font> and business may be <font color="blue">adversely</font> affected if we are     unable to protect our <font color="blue">intellectual <font color="blue">property rights</font></font> or <font color="blue">infringe upon</font> the     <font color="blue">intellectual <font color="blue">property rights</font></font> of others</td>
    </tr>
    <tr>
      <td><font color="blue">Intellectual </font><font color="blue">property rights</font>, including <font color="blue">patent rights</font>, are <font color="blue">significant</font>     to our ongoing <font color="blue">operations</font> and <font color="blue">future opportunities</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">success will depend</font>,     in part, on our ability to secure our own <font color="blue">intellectual <font color="blue">property rights</font></font>     (eg, patents, copyrights, trademarks, trade secrets), obtain licenses to     <font color="blue">technology</font> owned <font color="blue">by third parties</font> when <font color="blue">necessary</font>, and conduct our business     <font color="blue">without infringing on</font> the <font color="blue">proprietary</font> rights of others</td>
    </tr>
    <tr>
      <td>There can be no     assurance, however, that our <font color="blue">proprietary</font> rights will provide us <font color="blue">significant</font>     protection or <font color="blue">commercial advantage</font> or that <font color="blue">measures taken</font> to protect our     <font color="blue">confidential</font> information <font color="blue">will adequately prevent</font> the <font color="blue">disclosure</font> or misuse of     such <font color="blue">confidential</font> information</td>
    </tr>
    <tr>
      <td>In addition, there can be no assurance that,     in the future, a <font color="blue"><font color="blue">third party</font> will</font> not assert that we are violating their     <font color="blue">proprietary</font> rights, including that our technologies, products or services     infringe their patents</td>
    </tr>
    <tr>
      <td>In that event, we <font color="blue">could incur</font> substantial costs and     diversion of the time and attention of <font color="blue">management</font> and <font color="blue">technical personnel</font> in     defending  <font color="blue">ourselves against</font> any such claims</td>
    </tr>
    <tr>
      <td>Any <font color="blue">meritorious</font> claim of     intellectual property infringement against us could have a material adverse     effect on our <font color="blue">competitive position</font> and business</td>
    </tr>
    <tr>
      <td>We may not be able to <font color="blue">successfully integrate</font> our recently acquired business     into our current business <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We recently completed an <font color="blue">acquisition</font> of <font color="blue">ClickFind </font>and its product     suite</td>
    </tr>
    <tr>
      <td>This <font color="blue">new <font color="blue">product suite</font></font>, now called DATATRAK eClinical™, will play a     <font color="blue">significant</font> role in our efforts to continue to be a leading <font color="blue">ASP for the EDC     </font>industry</td>
    </tr>
    <tr>
      <td>We may not be able to <font color="blue">successfully integrate</font> and <font color="blue">profitably manage</font>     <font color="blue">ClickFind </font>and our new software offering without substantial costs, delays or     other problems</td>
    </tr>
    <tr>
      <td><font color="blue">Acquisitions </font><font color="blue">also may involve</font> a number of <font color="blue">special risks</font>,     including adverse short-term effects on our reported operating results,     <font color="blue">potentially dilutive issuances</font> of <font color="blue">equity securities</font>, the incurrence of debt     and contingent liabilities, diversion of <font color="blue">management</font>’s attention, dependence     <font color="blue">on retention hiring</font> and training of <font color="blue">key personnel</font> and <font color="blue">risks associated with</font>     <font color="blue">unanticipated problems</font> or <font color="blue">legal liabilities</font> some or all of <font color="blue">which could</font> have     a  material  adverse effect on our business, results of <font color="blue">operations</font> and     <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">will incur increased costs associated with</font> the <font color="blue">integration</font> of our new     <font color="blue">product suite</font></td>
    </tr>
    <tr>
      <td>All <font color="blue"><font color="blue">clinical trial</font>s</font> currently being performed with DATATRAK EDC® will     <font color="blue">continue through conclusion with</font> that <font color="blue">product suite</font></td>
    </tr>
    <tr>
      <td>At this time, it is     anticipated that the DATATRAK EDC® <font color="blue">platform will</font> be utilized in these, and     perhaps some new, <font color="blue"><font color="blue">clinical trial</font>s</font> until the end of 2009</td>
    </tr>
    <tr>
      <td>As such, we will     <font color="blue">provide two different architectures</font> for the use of <font color="blue">technology</font> in clinical     <font color="blue">trials until current trials</font>, and perhaps future trials, using the previous     platform are finished</td>
    </tr>
    <tr>
      <td>We will incur <font color="blue">additional</font> costs by continuing to     support  and  provide,  as  needed,  <font color="blue">appropriate <font color="blue">service packs</font></font> for the     maintenance of DATATRAK EDC® <font color="blue">as well as supporting</font> and <font color="blue">providing appropriate</font>     <font color="blue">service packs</font> for the maintenance of DATATRAK eClinical™</td>
    </tr>
    <tr>
      <td>We <font color="blue">will also incur</font>     <font color="blue">additional</font> costs to integrate the DATATRAK eClinical™ product into our     current operating systems</td>
    </tr>
    <tr>
      <td>10       _________________________________________________________________           Furthermore, our two product offerings will run on parallel systems, as such     we  will incur <font color="blue">additional</font> costs of maintaining <font color="blue">two parallel production</font>     systems</td>
    </tr>
    <tr>
      <td>DATATRAK eClinical™, which has been used in many <font color="blue">clinical trails</font> in     nineteen  separate  countries,  has  never  been  utilized  in a large     multi-national <font color="blue">clinical trial</font> with over 1cmam000 patients</td>
    </tr>
    <tr>
      <td>As such, we are     investing in <font color="blue">additional</font> infrastructure, so that DATATRAK eClinical™ can be     scaled to meet the needs of <font color="blue"><font color="blue">clinical trial</font>s</font> with such large volumes of data     and the software performs to the level of <font color="blue">satisfaction</font> that our customers     have  come  to  expect</td>
    </tr>
    <tr>
      <td>We  <font color="blue">may incur unforeseen costs</font> if <font color="blue">significant</font>     <font color="blue">modification</font> and testing become <font color="blue">necessary</font> to ensure the <font color="blue">scalability</font> of     DATATRAK eClinical™</td>
    </tr>
    <tr>
      <td>The price of our <font color="blue"><font color="blue">common shares</font> could</font> be <font color="blue">adversely</font> affected by the dilution     caused by the <font color="blue"><font color="blue">common shares</font> issued</font> in our recently completed <font color="blue">acquisition</font></td>
    </tr>
    <tr>
      <td><font color="blue">In <font color="blue">February </font></font>2006, we issued 1cmam026cmam522 of our <font color="blue">unregistered <font color="blue">common shares</font></font>     to the <font color="blue">former <font color="blue">shareholders</font></font> of <font color="blue">ClickFind </font>as part of the <font color="blue">acquisition</font> of the     <font color="blue">outstanding stock</font> of ClickFind</td>
    </tr>
    <tr>
      <td>These 1cmam026cmam522 <font color="blue">common shares</font> represent     approximately 9dtta0prca of our outstanding <font color="blue">common shares</font>, as of <font color="blue">February </font>28,     2006</td>
    </tr>
    <tr>
      <td>Sales of a substantial number of these <font color="blue">common shares</font> in the public     <font color="blue">market could depress</font> the <font color="blue">market price</font> of our <font color="blue">common shares</font></td>
    </tr>
    <tr>
      <td>The perceived     risk resulting from the sale of these <font color="blue"><font color="blue">common shares</font> could</font> cause some of our     <font color="blue">shareholders</font> to sell their <font color="blue">common shares</font>, thus causing the price of our     <font color="blue">common shares</font> to <font color="blue">further decline</font></td>
    </tr>
    <tr>
      <td>In addition, the <font color="blue">downward pressure on</font> the     price of our <font color="blue"><font color="blue">common shares</font> could</font> cause some of our <font color="blue">shareholders</font> to engage in     short sales of our <font color="blue">common shares</font>, which may cause the price of our common     shares to <font color="blue">decline even further</font></td>
    </tr>
    <tr>
      <td>We have Anti-takeover Provisions and Preferred Share Purchase Rights          Our Articles of Incorporation and By-Laws <font color="blue">contain provisions</font> that may     discourage a <font color="blue"><font color="blue">third party</font> from</font> acquiring, or attempting to acquire us</td>
    </tr>
    <tr>
      <td><font color="blue">These     </font><font color="blue">provisions could limit</font> the price that <font color="blue">certain investors might</font> be willing to     pay for our <font color="blue">common shares</font></td>
    </tr>
    <tr>
      <td>In <font color="blue">addition preferred shares</font> of our stock can be     issued by our Board of Directors, without shareholder approval, whether     under our <font color="blue">shareholder rights</font> plan or for other uses determined by the Board</td>
    </tr>
    <tr>
      <td>The issuance of preferred shares may <font color="blue">adversely</font> affect the rights of common     <font color="blue">shareholders</font>, the <font color="blue">market price</font> of our <font color="blue">common shares</font> and may make it more     <font color="blue">difficult</font> for a <font color="blue">third party</font> to acquire a majority of our <font color="blue">outstanding common</font>     shares</td>
    </tr>
  </tbody>
</table>